Latest News about CSLLY
Recent news which mentions CSLLY
From Benzinga
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
December 13, 2023
From Benzinga
From Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
March 20, 2023
From Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
From Benzinga
From Benzinga
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
November 02, 2022
From InvestorPlace
From Benzinga
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
August 22, 2022
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.